Randomized trial · people

Semaglutide: 24% lower risk of major kidney events in FLOW

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For people with type 2 diabetes and chronic kidney disease, this large trial links semaglutide to fewer serious kidney events and fewer deaths from heart causes than placebo over a median of 3.4 years.

Kind
Randomized trial
Studied in
People
Number studied
3533
Published
2024
Journal
N Engl J Med

What they tested

The team tested whether weekly semaglutide lowers the risk of kidney failure, heart-related death and other serious outcomes in people with both type 2 diabetes and chronic kidney disease.

How the study was done

A randomized, placebo-controlled trial in 3533 people with type 2 diabetes and chronic kidney disease, who got either a 1.0 mg weekly semaglutide shot under the skin or placebo (a dummy shot). Median follow-up was 3.4 years, and the trial was stopped early on the advice given at a planned interim analysis.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main outcome combined kidney failure, a drop of at least 50% in eGFR (an estimate of how well the kidneys filter blood), and death from kidney or heart causes. It happened 331 times in the semaglutide group and 410 times in the placebo group, a 24% lower risk (hazard ratio 0.76; 95% CI 0.66 to 0.88). Death from heart and blood vessel causes was also lower (hazard ratio 0.71), as were major cardiovascular events (hazard ratio 0.82) and death from any cause (hazard ratio 0.80). eGFR fell more slowly each year with semaglutide, by 1.16 ml per minute per 1.73 m2, and serious side effects were reported in 49.6% of the semaglutide group versus 53.8% of the placebo group.

What it doesn’t show

The trial included only people with type 2 diabetes and chronic kidney disease within set eGFR and urine albumin ranges, tested a single 1.0 mg dose, and was stopped early. It was funded by Novo Nordisk.

The paper

Perkovic et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo